Login to Your Account

Clinic Roundup

Wednesday, August 1, 2012
• Lixte Biotechnology Holdings Inc., of East Setauket, N.Y., said the FDA cleared the firm for a Phase I trial of cancer compound LB-100. The company also said it raised $2.5 million to initiate the trial and continue drug discovery research through an offering to holders of warrants for exercising their rights in cash.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription